KPV Under FDA Review for Wound Healing and Inflammatory Conditions

KPV — a tripeptide studied for its anti-inflammatory properties — is scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026. The FDA's briefing document evaluates KPV for wound healing and inflammatory conditions.

Why KPV is drawing attention

KPV appears in gut-health and immune-support discussions, and its inclusion on the PCAC agenda — with a published FDA evaluation — signals that the agency is actively assessing its place in the 503A framework.

Key details

• Evaluated uses: wound healing and inflammatory conditions.
• Reviewed on Day 1 (July 23, 2026).
• Public comment: Docket #FDA-2026-N-2979, deadline July 9, 2026.

This article is for educational purposes and summarizes publicly reported regulatory developments as of July 1, 2026. It is not medical, legal, or regulatory advice. FDA advisory committee reviews are evaluations, not approvals, and outcomes may change. Newtropin is a wellness marketing firm and not a licensed pharmacy.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.